The potential of gallic acid as a radiosensitizer on human prostate cancer: A systematic review of preclinical studies

Agung Tri Cahyono, Melva Louisa, Tiara Bunga Mayang Permata, Handoko, Endang Nuryadi, Henry Kodrat, Heri Wibowo, Agus Rizal Ardy Hariandy Hamid, Sri Mutya Sekarutami, Soehartati Argadikoesoema Gondhowiardjo

Research output: Contribution to journalReview articlepeer-review

Abstract

Prostate adenocarcinoma accounts for majority of prostate cancer cases, and it was found to be highly radioresistant. Gallic acid is a phenolic acid naturally occurring in many plants, reported to exhibit biological activities in eliminating cancer cell lines and xenografts. The purpose of this study is to review gallic acid as a potential radiosensitizer agent in prostate cancer treatment. Article search was conducted in PubMed, EBSCO, and Scopus. 11 studies using different cell lines including DU145, PC-3, LNCaP, and 22Rv1 xenograft of human prostate cancer were reviewed in this paper. Gallic acid acts as a radiosensitizer mainly by increasing caspase-3 and caspase-9 activation resulting in apoptosis, while also reducing intracellular CDKs, cyclins, and cdc25 phosphatases ultimately causing G2-M cell cycle arrest. Gallic acid has a potential to be a new radiosensitizer compound in prostate cancer treatment. Additional clinical studies using gallic acid derivatives with lower hydrophilicity are needed.

Original languageEnglish
Pages (from-to)246-254
Number of pages9
JournalMalaysian Journal of Medicine and Health Sciences
Volume17
Issue number2
Publication statusPublished - Apr 2021

Keywords

  • Apoptosis
  • Gallic acid
  • Prostate cancer
  • Radiobiology
  • Radiotherapy

Fingerprint Dive into the research topics of 'The potential of gallic acid as a radiosensitizer on human prostate cancer: A systematic review of preclinical studies'. Together they form a unique fingerprint.

Cite this